Latest News
The market has priced Google as if it is losing the AI race, but what is happening under the hood tells a different story.
Via The Motley Fool · October 7, 2026
VCSH offers a 4.6% yield and lower expense ratio, while VTES provides federally tax-free income for conservative investors seeking stable returns.
Via The Motley Fool · October 7, 2026
ServiceNow pairs faster growth with steady profits. UiPath trades at a lower valuation, though a one-time tax benefit inflated its fiscal 2026 profit.
Via The Motley Fool · October 7, 2026
These companies are already capitalizing on AI. It may just be the beginning.
Via The Motley Fool · October 7, 2026
Micron posted a huge beat with even stronger guidance, yet the stock shrugged, and the reason matters for what comes next.
Via The Motley Fool · October 7, 2026
While most investors chase the obvious AI names, one chip stock is quietly setting up as the better opportunity.
Via The Motley Fool · October 7, 2026
Archer Aviation's eVTOL could be the next big thing in aviation. Will air taxis be enough to invite Archer into the trillion-dollar club?
Via The Motley Fool · October 7, 2026
Disney (NYSE: DIS) licensed titles like "Percy Jackson" and "Ice Age" to Netflix (NASDAQ: NFLX) amid linear TV decline and heavy debt, highlighting Netflix's cash flow and margin advantages.
Via MarketBeat · October 7, 2026
Volatus Aerospace Chief Financial Officer Abhinav Singhvi said the company is positioning its commercial drone operations, aviation experience and defense technology capabilities to address growing demand for intelligence, surveillance and reconnaissance systems.
Speaking at a company presentation,
Via MarketBeat · October 7, 2026
AI-driven memory sales hit records as 78% of revenue came from AI infrastructure businesses.
Via The Motley Fool · October 7, 2026
Kurzius doubled his direct stake in the medical device company despite a 19% one-year stock decline, signaling confidence in COO's turnaround prospects.
Via The Motley Fool · October 7, 2026
Revenue grew 6.5% as Food Safety and Animal Safety segments both expanded.
Via The Motley Fool · October 7, 2026
AI is all the rage right now, but the mania could cool off quickly, without warning.
Via The Motley Fool · October 7, 2026
SpaceX is reportedly seeking to raise a fresh $40 billion of debt.
Via The Motley Fool · October 7, 2026
You don't need a time machine to get rich in the stock market. You just need discipline, which may mean establishing a hands-off approach to saving for retirement even when you don't want to.
Via The Motley Fool · October 7, 2026
Berkshire Hathaway is already a $1 trillion company.
Via The Motley Fool · October 7, 2026
Worthington Steel looks like it earned a profit in Q1, but actually lost money.
Via The Motley Fool · October 7, 2026
DraftKings launched its CFTC-regulated DKeX prediction market exchange, targeting up to $800 million in revenue by 2027 as the stock trades near 52-week lows amid sportsbook revenue decline.
Via MarketBeat · October 7, 2026
D-Wave is growing revenue at nearly 180% while Rigetti trades at a lower valuation, but both burn cash heavily and face unproven commercial roadmaps.
Via The Motley Fool · October 7, 2026
GE's former energy business is still reaping the rewards of the AI boom.
Via The Motley Fool · October 7, 2026
A test equipment giant's robotics arm is chasing physical AI with an early playbook that echoes Amazon's historic rise.
Via The Motley Fool · October 7, 2026
Legal issues and macroeconomic headwinds pose significant challenges for the real estate company.
Via The Motley Fool · October 7, 2026
Constellation Brands (NYSE:STZ) reiterated its fiscal 2027 outlook after reporting second-quarter results that Chief Executive Officer Nick Fink said exceeded the company’s expectations. The company maintained its comparable earnings-per-share guidance of $11.20 to $11.90 and said it could finish at
Via MarketBeat · October 7, 2026
First Phosphate (NASDAQ:PHOS) outlined progress on its Quebec phosphate development plans, including government support, resource-growth results, proposed financing arrangements and a targeted path to initial production by the end of 2029 or early 2030.
During a presentation, CEO and Director John
Via MarketBeat · October 7, 2026
Keel purchased 4,701 shares at $53.18 each following a 21% year-long decline, signaling confidence in the medical device company's valuation.
Via The Motley Fool · October 7, 2026